Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
EJNMMI Research
Published in: EJNMMI Research 1/2017

Open Access 01-12-2017 | Original research

The extent to which standardized uptake values reflect FDG phosphorylation in the liver and spleen as functions of time after injection of 18F-fluorodeoxyglucose

Authors: Georgia Keramida, Constantinos D. Anagnostopoulos, A. Michael Peters

Published in: EJNMMI Research | Issue 1/2017

Login to get access

Abstract

Purpose

In FDG PET/CT, standardized uptake value (SUV) is used to measure metabolic activity but detects un-phosphorylated FDG as well as phosphorylated FDG (FDG6P). Our aim was to determine the proportions of intrahepatic and intrasplenic FDG that are phosphorylated after FDG injection and compare them with SUVs.

Methods

Sixty patients undergoing whole-body PET/CT 60 min post-injection of FDG first had dynamic PET imaging for 30 min with measurement of hepatic and splenic FDG clearances using Patlak-Rutland analysis. The gradient of the Patlak-Rutland plot, which is proportional to clearance (Ki), was normalized to the intercept, which is proportional to FDG distribution volume (V(0)) with the same proportionality constant. Using measured values of Ki/V(0), FDG6P/FDG ratios as functions of time in the two organs were measured for assumed FDG blood disappearance half-times of 40, 50 and 60 min. Hepatic and splenic SUVs were measured from whole-body PET/CT.

Results

The mean (SD) Ki/V(0) was 0.0036 (0.0021) and 0.0060 (0.0041) ml/min/ml for the liver and spleen, respectively, but the hepatic SUV was 1.36-fold higher than the splenic SUV. This discrepancy was explained by the hepatic V(0) being 1.6-fold higher than the splenic V(0). The percentages of FDG phosphorylated 60 min post-injection were 27, 25 and 23% for the liver and 39, 36 and 34% for the spleen, for blood clearance half-times of 40, 50 and 60 min, respectively. SUV indices correlated poorly with Ki/V(0) for both organs.

Conclusions

SUV is largely determined by un-phosphorylated FDG in dynamic exchange with blood FDG, explaining the poor correlations between SUV indices and Ki/V(0).
Appendix
Available only for authorised users
Literature
1.
Choi Y, Hawkins RA, Huang SC, et al. Evaluation of the effect of glucose ingestion and kinetic model configurations of FDG in the normal liver. J Nucl Med. 1994;35:818–23.PubMed
2.
Iozzo P, Geisler F, Oikonen V, et al. Insulin stimulates liver glucose uptake in humans: an 18F-FDG PET Study. J Nucl Med. 2003;44:682–9.PubMed
3.
Munk OL, Bass L, Roelsgaard K, Bender D, Hansen SB, Keiding S. Liver kinetics of glucose analogs measured in pigs by PET: importance of dual-input blood sampling. J Nucl Med. 2001;42:795–801.PubMed
4.
Borra R, Lautamaki R, Parkkola R, et al. Inverse association between liver fat content and hepatic glucose uptake in patients with type 2 diabetes mellitus. Metabolism. 2008;57:1445–51.CrossRefPubMed
5.
Lindholm P, Minn H, Leskinen-Kallio S, et al. Influence of the blood glucose concentration on FDG uptake in cancer—a PET study. J Nucl Med. 1993;34:1–6.PubMed
6.
Namba H, Nakagawa K, Iyo M, et al. A simple method for measuring glucose utilization of insulin-sensitive tissues by using the brain as a reference. Eur J Nucl Med. 1994;21:228–31.CrossRefPubMed
7.
Hasselbalch SG, Knudsen GM, Capaldo B, et al. Blood-brain barrier transport and brain metabolism of glucose during acute hyperglycemia in humans. J Clin Endocrinol Metab. 2001;86:1986–90.PubMed
8.
Boellaard R, O’Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181–200.CrossRefPubMed
9.
Abikhzer G, Alabed YZ, Azoulay L, Assayag J, Rush C. Altered hepatic metabolic activity in patients with hepatic steatosis on FDGPET/CT. Am J Roentgenol. 2011;196:176–80.CrossRef
10.
Abele JT, Fung CI. Effect of hepatic steatosis on liver FDG uptake measured in mean standard uptake values. Radiology. 2010;254:917–24.CrossRefPubMed
11.
Lin CY, Lin WY, Lin CC, et al. The negative impact of fatty liver on maximum standard uptake value of liver on FDG PET. Clin Imaging. 2011;35:437–41.CrossRefPubMed
12.
Kumar R, Xiu Y, Yu JQ, et al. 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med. 2004;45:2058–62.PubMed
13.
Bural GG, Torigian DA, Burke A, et al. Quantitative assessment of the hepatic metabolic volume product in patients with diffuse hepatic steatosis and normal controls through use of FDG-PET and MR imaging: a novel concept. Mol Imaging Biol. 2010;12:233–9.CrossRefPubMed
14.
Kim EJ, Kim S, Kang DO, et al. Metabolic activity of the spleen and bone marrow in patients with acute myocardial infarction evaluated by 18F-fluorodeoxyglucose positron emission tomographic imaging. Circ Cardiovasc Imaging. 2014;7:454–60.CrossRefPubMed
15.
Emami H, Singh P, MacNabb M, et al. Splenic metabolic activity predicts risk of future cardiovascular events: demonstration of a cardiosplenic axis in humans. JACC Cardiovasc Imaging. 2015;8:121–30.CrossRefPubMed
16.
Wollenweber T, Roentgen P, Schafer A, et al. Characterizing the inflammatory tissue response to acute myocardial infarction by clinical multimodality noninvasive imaging. Circ Cardiovasc Imaging. 2014;7:811–8.CrossRefPubMed
17.
Boellaard R, van Lingen A, Lammertsma AA. Experimental and clinical evaluation of iterative reconstruction (OSEM) in dynamic PET: quantitative characteristics and effects on kinetic modeling. J Nucl Med. 2001;42:808–17.PubMed
18.
Wakita K, Imahori Y, Ido T, et al. Simplification for measuring input function of FDG PET: investigation of 1-point blood sampling method. J Nucl Med. 2000;41:1484–90.PubMed
19.
Shiozaki T, Sadato N, Senda M, et al. Noninvasive estimation of FDG input function for quantification of cerebral metabolic rate of glucose: optimization and multicenter evaluation. J Nucl Med. 2000;41:1612–8.PubMed
20.
Tsuchida T, Sadato N, Yonekura Y, et al. Noninvasive measurement of cerebral metabolic rate of glucose using standardized input function. J Nucl Med. 1999;40:1441–5.PubMed
21.
Huang J, O’Sullivan F. An analysis of whole body tracer kinetics in dynamic PET studies with application to image-based blood input function extraction. IEEE Trans Med Imaging. 2014;33:1093–108.CrossRefPubMedPubMedCentral
22.
Zhou S, Chen K, Reiman EM, Li DM, Shan B. A method of generating image-derived input function in a quantitative 18F-FDG PET study based on the shape of the input function curve. Nucl Med Commun. 2011;32:1121–7.CrossRefPubMed
23.
Vriens D, de Geus-Oei L-F, Oyen WJG, Visser EP. A curve-fitting approach to estimate the arterial plasma input function for the assessment of glucose metabolic rate and response to treatment. J Nucl Med. 2009;50:1933–9.CrossRefPubMed
24.
O’Sullivan F, Muzi M, Spence AM, et al. Nonparametric residue analysis of dynamic PET data with application to cerebral FDG studies in normals. J Am Stat Assoc. 2009;104(486):556–71.CrossRefPubMedPubMedCentral
25.
O’Sullivan F, Kirrane J, Muzi M, et al. Kinetic quantitation of cerebral PET-FDG studies without concurrent blood sampling: statistical recovery of the arterial input function. IEEE Trans Med Imaging. 2010;29:610–24.CrossRefPubMed
26.
27.
van der Weerdt AP, Klein LJ, Boellaard R, Visser CA, Visser FC, Lammertsma AA. Image-derived input functions for determination of MRGlu in cardiac (18)F-FDG PET scans. J Nucl Med. 2001;42:1622–9.PubMed
28.
de Geus-Oei LF, Visser EP, Krabbe PF, van Hoorn BA, Koenders EB, Willemsen AT, et al. Comparison of image-derived and arterial input functions for estimating the rate of glucose metabolism in therapy-monitoring 18F-FDG PET studies. J Nucl Med. 2006;47:945–9.PubMed
29.
Keramida G, Hunter J, Peters AM. Hepatic glucose utilisation in hepatic steatosis and obesity. Biosci Rep. 2016;36: article Identifier: e00402 DOI*: doi:10.​1042/​BSR20160381.
30.
Boer P. Estimated lean body mass as an index for normalization of body fluid volumes in man. Am J Physiol. 1984;247:F632–5.PubMed
31.
Ricci C, Longo R, Gioulis E, et al. Noninvasive in vivo quantitative assessment of fat content in human liver. J Hepatol. 1997;27:108–13.CrossRefPubMed
32.
Keramida G, Potts J, Bush J, Verma S, Dizdarevic, Peters AM. Accumulation of 18F-FDG in the liver in hepatic steatosis. Am J Roentgenol. 2014;203:643–8.CrossRef
33.
Cheng G, Alavi A, Lim E, Werner TJ, Del Bello CV, Akers SR. Dynamic changes of FDG uptake and clearance in normal tissues. Mol Imaging Bio. 2013;15:345–52.CrossRef
34.
Lee JW, Kim SK, Lee SM, Moon SH, Kim TS. Detection of hepatic metastases using dual-time-point FDG PET/CT scans in patients with colorectal cancer. Mol Imaging Biol. 2011;13:565–72.CrossRefPubMed
35.
Basu S, Kung J, Houseni M, Zhuang H, Tidmarsh GF, Alavi A. Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: implications for its utilization in assessing malignant lesions. Q J Nucl Med Mol Imaging. 2009;53:9–19.PubMed
36.
Chirindel A, Alluri KC, Tahari AK, et al. Liver standardized uptake value corrected for lean body mass at FDG PET/CT: effect of FDG uptake time. Clin Nucl Med. 2015;40:e17–22.CrossRefPubMed
37.
Mejia AA, Nakamura T, Masatoshi I, Hatazawa J, Masaki M, Watanuki S. Estimation of absorbed doses in humans due to intravenous administration of fluorine-18-fluorodeoxyglucose in PET studies. J Nucl Med. 1991;32:699–706.PubMed
38.
Price PM, Badawi RD, Cherry SR, Jones T. Ultra staging to unmask the prescribing of adjuvant therapy in cancer patients: the future opportunity to image micrometastases using total-body 18F-FDG PET scanning. J Nucl Med. 2014;55:696–7.CrossRefPubMedPubMedCentral
39.
Tragardh M, Moller N, Sorensen M. Methodologic considerations for quantitative 18F-FDGPET/CT studies of hepatic glucose metabolismin healthy subjects. J Nucl Med. 2015;56:1366–71.CrossRefPubMed
40.
Sugawara Y, Zasadny KR, Neuhoff AW, Wahl RL. Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology. 1999;213:521–5.CrossRefPubMed
41.
van den Hoff J, Oehme L, Schramm G, et al. The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG. EJNMMI Res. 2013;3(1):77.CrossRefPubMedPubMedCentral
42.
Keramida G, Dizdarevic S, Bush J, Potts J, Peters AM. Quantification of tumour 18F-FDG uptake: normalise to blood glucose or scale to liver uptake? Eur Radiol. 2015;25:2701–8.CrossRefPubMed
43.
44.
Bohte AE, van Werven JR, Bipat S, Stoker J. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol. 2011;21:87–97.CrossRefPubMed
45.
Keiding S, Munk OL, Schiøtt KM, Hansen SB. Dynamic 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography of liver tumours without blood sampling. Eur J Nucl Med. 2000;27:407–12.CrossRefPubMed
Metadata
Title
The extent to which standardized uptake values reflect FDG phosphorylation in the liver and spleen as functions of time after injection of 18F-fluorodeoxyglucose
Authors
Georgia Keramida
Constantinos D. Anagnostopoulos
A. Michael Peters
Publication date
01-12-2017
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2017
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-017-0254-7

Other articles of this Issue 1/2017

EJNMMI Research 1/2017 Go to the issue

Original research

Clinical value of fluorine-18α-methyltyrosine PET in patients with gliomas: comparison with fluorine-18 fluorodeoxyglucose PET

Original research

Carotid atherosclerotic plaques standardised uptake values: software challenges and reproducibility

Erratum

Erratum to: Test-retest analysis of a non-invasive method of quantifying [(11)C]-PBR28 binding in Alzheimer's disease

Original research

First in-human radiation dosimetry of 68Ga-NODAGA-RGDyK

Original research

Comparison of machine learning methods for classifying mediastinal lymph node metastasis of non-small cell lung cancer from 18F-FDG PET/CT images

Original research

Early assessment of response to induction therapy in acute myeloid leukemia using 18F-FLT PET/CT